Allosteric and ATP-Competitive Inhibitors of mTOR Effectively Suppress Tumor Progression-Associated Epithelial-Mesenchymal Transition in the Kidneys of Tsc2 +/- Mice

Ashley T. Jones, Jian Yang, Kalin Narov, Elizabeth P Henske, Julian R. Sampson and Ming Hong Shen

Institute of Medical Genetics, Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK

Abstract

In tuberous sclerosis (TSC)-associated tumors, mutations in the TSC genes lead to aberrant activation of the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway. mTORC1 signaling impacts many biological processes including the epithelial-mesenchymal transition (EMT), which is suggested to promote tumor progression and metastasis in various types of cancer. In this study, we report hybrid cells with epithelial and mesenchymal features in angiomyolipomas and partial EMT in carcinomas from TSC patients and describe a new model of EMT activation during tumor progression from cyst to papillary adenoma to solid carcinoma in the kidneys of Tsc2 +/- mice. Features of EMT occurred infrequently in TSC-associated cysts but increased as the lesions progressed through papillary adenoma to solid carcinoma where epithelial-mesenchymal hybrid cells were abundant, indicating partial EMT. We also compared the effects of the novel ATP-competitive mTOR inhibitor AZD2014 with the allosteric mTOR inhibitor rapamycin on EMT and tumor burden. Both AZD2014 and rapamycin potently suppressed EMT of renal tumors and effectively blocked tumor progression in Tsc2 +/- mice. These results suggest that partial EMT is a shared feature of TSC-associated renal tumors in humans and mice and occurs during TSC-associated tumor progression. EMT-related signaling pathways may represent therapeutic targets for tumors associated with mutations in the TSC genes.

Neoplasia (2019) 21, 731–739

Introduction

Tuberous sclerosis (TSC) is a tumor syndrome caused by mutations of the TSC1 or TSC2 gene [1]. Kidney lesions are one of the most frequent manifestations of TSC, with angiomyolipomas (AMLs) being the most common lesions. Despite the fact that most AMLs are benign tumors, their propensity for spontaneous hemorrhage can have life-threatening consequences. Other TSC-associated kidney lesions include oncocytoma, malignant AML, and renal cell carcinoma (RCC) [2–4]. RCC occurs in about 4% of TSC patients and is characterized by diagnosis at a young age and pathological heterogeneity with clear-cell, papillary, and chromophobe carcinoma subtypes. TSC-associated lesions are also observed in other organs including lymphangioleiomyomatosis (LAM) affecting the lungs, subependymal giant cell astrocytomas in the brain, cardiac rhabdomyomas, and facial angiofibromas. Mice heterozygous for Tsc1 +/- or Tsc2 +/- develop small cystic lesions in the kidneys detectable histologically from as early as 2 months. With aging, the number and size of lesions increase, and they progress to papillary and then solid malignancies, providing a valuable model for investigating...
mechanisms underlying tumor progression [5–8]. Human and mouse TSC-associated tumors show somatic loss of the corresponding second allele and aberrant activation of the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway [5,6,9,10].

mTORC1 plays a crucial role in the control of many biological activities such as cell growth, proliferation, and survival [11]. mTORC1 is also an important regulator of epithelial-mesenchymal transition (EMT) [12]. EMT is a cellular process that converts epithelial cells into cells with a mesenchymal phenotype and is coordinated by complex regulatory networks involving transcriptional control and epigenetic modifications [13,14]. EMT is critical for embryogenesis and is also implicated in wound healing and pathogenesis of disease. Activation of EMT is suggested to promote tumor initiation, progression, metastasis, and resistance to chemotherapy and immunotherapy in various types of cancer including renal cell carcinoma [15–17].

TSC-associated AML and LAM are associated with markers of EMT, although their cellular origin remains to be established [18,19]. The mesenchymal marker vimentin is also detected in some TSC-associated RCC, suggesting EMT [3]. AMLs shrink significantly in response to treatment with the allosteric mTOR inhibitor rapamycin and its derivatives [20–23], but the responses are partial, and tumors usually regrow after treatment withdrawal. Partial resistance to rapamycin or its derivatives is probably associated with loss of negative feedback regulation that leads to activation of AKT [24]. AZD2014, also known as vistusertib, is a novel ATP-competitive dual inhibitor of mTORC1 and mTORC2 and has shown dramatic suppression of EMT in hepatoma cells with significant antitumor effects in various cancer cell lines and xenograft mouse models of cancer [25–28].

In this study, we report hybrid cells with epithelial and mesenchymal features in AML and partial EMT in renal carcinomas from TSC patients and describe a new model of EMT activation during tumor progression in the kidneys of Tsc2<sup>−/−</sup> mice. We have also demonstrated that both AZD2014 and rapamycin effectively suppress EMT and block tumor progression. These results suggest that EMT-related signaling pathways may provide targets for treating tumors associated with mutations in the TSC genes.

Materials and Methods

Animal Procedures

Animal procedures were performed in accordance with the UK Home Office guidelines and approved by the Ethical Review Group of Cardiff University. As described previously, Tsc2<sup>−/−</sup> mice were backcrossed to balb/c strain [6]. To determine the effect of AZD2014 and rapamycin on EMT and molecular signaling and to compare the antitumor efficacy of AZD2014 with rapamycin, Tsc2<sup>−/−</sup> litter mates were randomly allocated into 3 groups of 8, balanced for gender. Animals were treated with vehicle, AZD2014 (20 mg/kg, maximum tolerated dose), and rapamycin (5 mg/ kg) for 2 months from the age of 14 months through intraperitoneal injection 5 times a week. At the end of treatment, animals were humanely killed for assessment of tumor burden and analysis of protein expression and phosphorylation in normal tissues and tumor samples. AZD2014 (APEXBio, Houston, TX) at 4 mg/ml and rapamycin (LC Laboratories, Woburn, MA) at 1 mg/ml were prepared in vehicle solution (2.5% PEG-400, 2.5% Tween-80, and 2.5% DMSO) respectively.

Histology

Assessment of tumor burden in the kidneys of mice was performed as described previously [8]. Mouse kidneys were fixed in 10% buffered formalin saline for 24 hours, processed, and paraffin embedded. Six coronal sections of 5 µm were prepared at a 200-µm interval from both kidneys of each mouse, stained with hematoxylin/eosin, and scanned using an Aperio system (http://www.aperio.com/?gclid = CNXN-8by4a UCFCfNAodskg1w). Scanned images were used for lesion quantification using ImageJ (http://rsweb.nih.gov/ij). Lesion number was determined, and maximum cross-sectional whole area including noncellular spaces and cellular area of each renal lesion were measured. Tumor burdens were estimated from whole areas and cellular areas of all lesions (cystic, papillary, and solid), cystic/papillary lesions, and solid carcinomas, respectively. The assessment was conducted blindly with respect to treatment status.

Immunohistochemistry (IHC)

This study was approved by the Institutional Review Board of the Brigham and Women’s Hospital, Boston MA. Human tumor sections and mouse kidney sections were prepared as described above. Conventional IHC was performed as described previously [29]. Multiple sequential IHC (MS-IHC) was performed to colocalize multiple antigens in the same cells. A crucial step of MS-IHC was to completely strip previous primary antibodies to ensure efficiency and specificity of subsequent primary antibody-antigen reactions. The protocol used for stripping primary antibodies was modified from Kim et al. [30]. For MS-IHC, previous IHC-stained slides were incubated in xylene for 10 minutes to remove coverslips and then incubated at 50°C in a buffered solution containing 5% SDS, 0.5% mercaptoethanol, and 50 mm Tris–HCl (pH 7.5) for 60 minutes to strip primary antibodies, and finally, the protocol was followed for conventional IHC. SignalStain Boost Rabbit specific IHC Detection Reagent (Cell Signaling Technology, Danvers, MA) and ImmPACT NovaRED Peroxidase Substrate or ImmPACT VIP Peroxidase (HRP) Substrate (Vector Laboratories, Peterborough, UK) were used to stain antigens according to the kit suppliers’ instruction. IHC or MS-IHC stained slides were scanned to generate virtual slides for photo capture using an Aperio system. Primary antibodies were used for IHC against phosphorylated S6 ribosomal protein at S235/236, phosphorylated Akt at S473, E-cadherin, vimentin, FSP1, α-SMA (Cell Signaling Technology, Danvers, MA), Ki67, and active caspase 3 (Abcam, Cambridge, UK).

Western blot

Western blot was performed as described previously [29]. Protein extracts were prepared from normal tissues and tumor samples using AllPrep DNA/RNA/Protein Mini Kit (QIAGEN Ltd-UK, Crawley, UK). Proteins were purified according to the kit supplier’s instruction. Twenty micrograms of protein per sample was separated on NuPAGE 4%-12% Bis-Tris Gels (Fisher Scientific UK Ltd., Loughborough, UK) and transferred onto Amersham Protran Nitrocellulose Membrane (Immun-chem Limited, Hitchin, UK). Blots were analyzed with ECL Select Western Detection Kit (GE Healthcare UK Ltd., Little Chalfont, UK), and signals were detected using ChemiDoc Imaging System (UVG, Upland, CA). Horseradish peroxidase–conjugated secondary antibody against rabbit was used for Western blot (Cell Signaling Technology). Primary antibodies were used for Western blot against phosphorylated S6 ribosomal protein at S235/236, 4E-BP1 at T37/46, Akt at S473, Akt at T308, and E-cadherin, vimentin, β-actin (Cell Signaling Technology), phosphorylated PKC at T638 (Abcam);
phosphorylated MDM2 at S166, mTOR at S2448, and mTOR at S2481 (Sigma-Aldrich, Dorset, UK).

**Statistical Analysis**

The Mann-Whitney test was used to compare tumor burden between treatment groups. Two-tailed Fisher’s exact test was used to compare protein expression in tumor cells obtained by IHC between treatment groups. \( P < 0.05 \) was considered to be statistically significant. Analyses were performed using GraphPad Prism 7.03.

**Results**

**Expression of Epithelial and Mesenchymal Markers in Kidney Tumors of TSC patients and Tsc2+/- Mice**

We examined mTOR signaling and markers of epithelial and mesenchymal status in AML and RCC of TSC patients using MS-IHC. The MS-IHC technique was validated using mouse kidney sections as depicted in Supplementary Figure 1. Both mTORC1 and mTORC2 were activated in these human tumors as evidenced by increased phosphorylation of S6 and Akt (Figure 1A). E-cadherin was used as an epithelial marker, whereas vimentin, FSP1, and α-SMA were used as mesenchymal markers. As shown in Figure 1B, vimentin and FSP1 were consistently detected in human tumors as observed previously [31], while E-cadherin expression was also observed. Co-expression of E-cadherin and vimentin/FSP1 was observed in these tumors, indicating partial EMT in RCC and existence of hybrid cells with epithelial and mesenchymal features in AML (Figure 1B, Supplementary Figures 2 and 3). We then investigated mTOR signaling and EMT in renal lesions of Tsc2+/- mice using IHC on consecutive kidney sections. As reported previously [7], both mTORC1 and mTORC2 were activated in all renal lesions including cysts, papillary lesions, and solid malignancies as indicated by increased phosphorylation of S6 and Akt (Figure 2A). As shown in Figure 2A, E-cadherin was expressed in nearly all tumor cells of cystic and papillary lesions, but expression was lower, variable, and sometimes absent in tumor cells of carcinomas. In contrast, the expression of vimentin, FSP1, and α-SMA was minimal in cysts but increased in more advanced lesions (Figure 2A and B). The IHC images from consecutive kidney sections as depicted in Figure 2A show co-expression of both epithelial and mesenchymal markers in tumor cells, suggesting partial EMT [15]. To confirm this observation, MS-IHC was performed on the same kidney sections. Many hybrid epithelial-mesenchymal tumor cells were present as evidenced by co-expression of E-cadherin, vimentin, and FSP1 (Figure 2C, Supplementary Figures 4, 5, 5-1 and 5-2). These results suggest that partial EMT in TSC-associated renal tumors is a shared feature by human and mouse and that activation of EMT increases as tumors progress from cysts to papillary adenomas and solid carcinomas.
Suppression of EMT by AZD2014 and Rapamycin in Renal Tumors of Tsc2+/− Mice

We then asked if mTOR inhibitors suppress EMT in renal lesions. We first determined that the maximum tolerated dose of AZD2014 in Tsc2+/− mice was 20 mg/kg body weight per day via intraperitoneal injection in a pilot study of 2 weeks of treatment. Three groups of eight randomly allocated Tsc2+/− mice were then treated for 2 months, beginning at age 14 months, with vehicle, AZD2014 (20 mg/kg), or rapamycin (5 mg/kg) via intraperitoneal injection. Following treatment, we examined protein levels of E-cadherin, vimentin, FSP1, and α-SMA in different types of renal tumors from cystic/papillary lesions to solid malignancies. Black arrows point to tumor cells stained by vimentin, FSP1, or α-SMA in cystic/papillary lesions. Black lines are scale bars.

Figure 2. mTOR signaling and protein levels of epithelial and mesenchymal markers in renal lesions of Tsc2+/− mice. (A) mTOR signaling and expression of E-cadherin, vimentin, FSP1, and α-SMA. Adjacent kidney sections prepared from 16-month-old Tsc2+/− mice were used for IHC. Representative IHC-stained sections were presented to show phosphorylation of S6 at S235/236 and Akt at S473, and protein levels of E-cadherin, vimentin, FSP1, and α-SMA in different types of renal tumors from cystic/papillary lesions to solid malignancies. Black arrows point to tumor cells stained by vimentin, FSP1, or α-SMA in cystic/papillary lesions. Black lines are scale bars. (B) Expression of vimentin. Kidney sections prepared from 16-month-old Tsc2+/− mice were used for IHC. Representative IHC-stained sections were presented to show different types of renal tumors negative (−) or positive (+) for vimentin. Higher-power views of boxed areas are presented next to the corresponding lower-power images. Black lines are scale bars. (C) Identification of tumor cells with partial EMT. Kidney sections prepared from 16-month-old Tsc2+/− mice were used for MS-IHC. The same kidney sections were subjected to three rounds of IHC to sequentially detect three indicated antigens. Representative images were presented to show examples of tumor cells co-expressing E-cadherin and vimentin/FSP1 in circled areas. Higher-power views of boxed areas are presented next to the corresponding lower-power images. Around 60.1% (11.6%-96.8%) of tumor cells co-expressed E-cadherin and vimentin (and or FSP1) as estimated from 10 mouse renal carcinomas. Black lines are scale bars.

Suppression of EMT by AZD2014 and Rapamycin in Renal Tumors of Tsc2+/− Mice

We then asked if mTOR inhibitors suppress EMT in renal lesions. We first determined that the maximum tolerated dose of AZD2014 in Tsc2+/− mice was 20 mg/kg body weight per day via intraperitoneal injection in a pilot study of 2 weeks of treatment. Three groups of eight randomly allocated Tsc2+/− mice were then treated for 2 months, beginning at age 14 months, with vehicle, AZD2014 (20 mg/kg), or rapamycin (5 mg/kg) via intraperitoneal injection. Following treatment, we examined protein levels of E-cadherin, vimentin, and FSP1 by IHC on kidney sections. We found that the protein levels of vimentin and FSP1 were significantly attenuated in cystic/papillary lesions treated by AZD2014 or rapamycin compared to vehicle (Figure 3). The proportion of cystic/papillary lesions with one or more tumor cells positive for either vimentin or FSP1 was also significantly reduced after treatment by AZD2014 or rapamycin (Figure 3, Supplementary Tables 1 and 2). Furthermore, the protein levels of both vimentin and FSP1 were dramatically reduced in solid carcinomas treated by AZD2014 or rapamycin compared to vehicle (Figure 4A), while the E-cadherin level was variable. Protein samples were also prepared from solid carcinomas after treatment for Western analysis. Consistently, Western analysis also demonstrated reduced vimentin and variable E-cadherin levels in solid carcinomas treated by AZD2014 or rapamycin compared to vehicle (Figure 4B). These findings suggest that both AZD2014 and rapamycin suppress EMT in most renal tumors of Tsc2+/− mice. However, in one large solid carcinoma from a Tsc2+/− mouse treated with AZD2014, protein levels of vimentin and FSP1 were not significantly affected, which were consistent with phosphorylation levels of S6 and Akt (Supplementary Figure 6), suggesting resistance to AZD2014.

Inhibition of mTORC1 and mTORC2 by AZD2014 and Rapamycin in Renal Tumors of Tsc2+/− Mice

We performed IHC and Western analysis to determine the effects of AZD2014 and rapamycin on mTOR signaling using kidney sections and protein samples prepared from solid carcinomas, as
described above. Phosphorylation of mTOR at S2448, S6 at s235/236, and 4E-BP1 at T37/46 was used as readouts of mTORC1 activity, and phosphorylation of mTOR at S2481, Akt at S473 and T450, PKCα at T638, and the Akt substrate MDM2 at S166 was used as readouts of mTORC2 activity. As expected, AZD2014 markedly reduced phosphorylation of all mTORC1 and mTORC2 markers in all renal tumors and normal kidneys (Figure 5, Supplementary Figure 7). AZD2014 also reduced phosphorylation of Akt at T308 (Figure 5B). Rapamycin significantly reduced phosphorylation of all mTORC1 markers in all renal tumors and normal kidneys (Figure 5, Supplementary Figure 7). AZD2014 also reduced phosphorylation of Akt at T308 (Figure 5B). Rapamycin significantly reduced phosphorylation of all mTORC1 markers in all renal tumors and normal kidneys (Figure 5, Supplementary Figure 7). AZD2014 also reduced phosphorylation of Akt at T308 (Figure 5B). Rapamycin significantly reduced phosphorylation of all mTORC1 markers in all renal tumors and normal kidneys (Figure 5, Supplementary Figure 7). AZD2014 also reduced phosphorylation of Akt at T308 (Figure 5B). Rapamycin significantly reduced phosphorylation of all mTORC1 markers in all renal tumors and normal kidneys (Figure 5, Supplementary Figure 7). AZD2014 also reduced phosphorylation of Akt at T308 (Figure 5B). Rapamycin significantly reduced phosphorylation of all mTORC1 markers in all renal tumors and normal kidneys (Figure 5, Supplementary Figure 7). AZD2014 also reduced phosphorylation of Akt at T308 (Figure 5B). Rapamycin significantly reduced phosphorylation of all mTORC1 markers in all renal tumors and normal kidneys (Figure 5, Supplementary Figure 7). AZD2014 also reduced phosphorylation of Akt at T308 (Figure 5B). Rapamycin significantly reduced phosphorylation of all mTORC1 markers in all renal tumors and normal kidneys (Figure 5, Supplementary Figure 7). AZD2014 also reduced phosphorylation of Akt at T308 (Figure 5B). Rapamycin significantly reduced phosphorylation of all mTORC1 markers in all renal tumors and normal kidneys (Figure 5, Supplementary Figure 7). AZD2014 also reduced phosphorylation of Akt at T308 (Figure 5B). Rapamycin significantly reduced phosphorylation of all mTORC1 markers in all renal tumors and normal kidneys (Figure 5, Supplementary Figure 7). AZD2014 also reduced phosphorylation of Akt at T308 (Figure 5B). Rapamycin significantly reduced phosphorylation of all mTORC1 markers in all renal tumors and normal kidneys (Figure 5, Supplementary Figure 7). AZD2014 also reduced phosphorylation of Akt at T308 (Figure 5B). Rapamycin significantly reduced phosphorylation of all mTORC1 markers in all renal tumors and normal kidneys (Figure 5, Supplementary Figure 7). AU2014 potently inhibited mTORC1 and mTORC2, while rapamycin inhibited mTORC1 potently but partially inhibited mTORC2 in renal tumors.

**Effective blocking of Tumor Progression by AZD2014 and Rapamycin in the kidneys of Tsc2+/- Mice**

Both AZD2014 and rapamycin strikingly inhibited proliferation of tumor cells in the kidneys of Tsc2+/- mice, but no significant changes in apoptosis were detected with either drug given individually (Supplementary Figure 8). We therefore sought to compare the antitumor efficacy of AZD2014 with rapamycin in Tsc2+/- mice. Animals treated for 2 months as described above were used for tumor burden assessment. All animals survived until termination of treatment, and no animals showed significant weight loss or other observable clinical signs. Tumor burden was determined by analyzing all lesions (cystic/papillary/solid), cystic/papillary lesions, and solid carcinomas in the kidneys, respectively. Both AZD2014 and rapamycin significantly reduced the total number (P = .0012; P = .0002), size (P = .0047; P = .0047), and cellular area (P = .0047; P = .0002) of all lesions (Figure 6, Supplementary Table 3). Similarly, both AZD2014 and rapamycin significantly reduced the
total number ($P = .0017; P = .0002$) and cellular area ($P = .0002; P = .0148$) of cystic/papillary lesions (Figure 6, Supplementary Table 4). AZD2014 significantly reduced the total size of cystic/papillary lesions ($P = .0019$). Rapamycin also appeared to reduce the total size of cystic/papillary lesions but not statistically significant ($P = .5737$). Further, both AZD2014 and rapamycin significantly

**Figure 4.** Effect of AZD2014 and rapamycin on EMT in solid tumors of Tsc2$^{+/−}$ mice. (A) IHC analysis. Adjacent kidney sections prepared from 16-month-old Tsc2$^{+/−}$ mice treated with vehicle, AZD2014, or rapamycin were used to analyze EMT by IHC. Representative IHC-stained images were presented to show protein levels of vimentin, FSP1, and C-cadherin in solid tumors. Black lines are scale bars. (B) Western blot analysis. Proteins were prepared from solid carcinomas dissected from Tsc2$^{+/−}$ mice treated for 2 months from the age of 14 months with vehicle, AZD2014, or rapamycin. Beta-actin was used as a loading control. Representative Western blots were presented to show expression levels of vimentin and E-cadherin.

**Figure 5.** Effect of AZD2014 and rapamycin on mTORC1 and mTORC2 in renal tumors of Tsc2$^{+/−}$ mice. (A) IHC analysis. Adjacent kidney sections prepared from 16-month-old Tsc2$^{+/−}$ mice treated with vehicle, AZD2014, or rapamycin were used for IHC analysis. Representative IHC-stained sections were presented to show phosphorylation of mTOR at S6 at S235/236 and Akt at S473 in renal tumors. Black lines are scale bars. (B) Western blot analysis. Proteins were prepared from solid carcinomas dissected from Tsc2$^{+/−}$ mice treated for 2 months from the age of 14 months with vehicle, AZD2014, or rapamycin. Beta-actin was used as a loading control. Representative Western blots were presented to show phosphorylation of mTOR at S2448 and S2481, S6 at S235/236, 4E-BP1 at T37/46, Akt at T308 and S473, PKCα at T638, MDM2 at S166, and MDM2 at S166.
reduced total number \((P = .0003; P = .0003)\), size \((P = .0095; P = .0002)\), and cellular area \((P = .0095; P = .0002)\) of solid carcinomas (Figure 6, Supplementary Table 5). No significant difference in antitumor efficacy was found between AZD2014 and rapamycin. These results indicate that both AZD2014 and rapamycin effectively block tumor progression in the kidneys of \(Tsc2^{+/-}\) mice.

**Discussion**

We examined epithelial and mesenchymal markers in renal tumors from TSC patients and \(Tsc2^{+/-}\) mice. We observed partial EMT in TSC-RCC, and hybrid cells with epithelial and mesenchymal features in AML from TSC patients. EMT in sporadic RCC has been associated with poor prognosis [32], and vimentin expression was previously reported in TSC-associated RCC [3]. TSC-associated renal AML and pulmonary LAM cells are considered to be mesenchymal tumors, but their origin remains to be established. EMT has been suggested to contribute to the pathogenesis of these lesions [18,19,33]. Our findings in TSC-associated human tumors are consistent with these observations. We also found that features consistent with partial EMT developed during tumor progression from cysts to papillary adenomas and solid carcinomas in \(Tsc2^{+/-}\) mice. Partial EMT, but not necessarily complete EMT, is implicated in tumor progression and metastasis, and tumor cells undergoing partial EMT appear to have some attributes of cancer stem cells [15,16,34–38]. The hybrid or intermediate epithelial-mesenchymal states of partial EMT observed in circulating tumor cells of cancer patients may confer plasticity and facilitate reverse mesenchymal-epithelial transition that is required for metastatic colonization [37].

Until recently, most EMT-related studies to improve our understanding of the mechanisms underlying tumor progression and metastasis were performed in cultured tumor cells or in xenograft tumor models. In a transgenic mouse model of pancreatic cancer, the intermediate epithelial-mesenchymal states were determined by lineage tracking through a \(Pdx1-Cre; Rosa26^{YP}\) system in premalignant lesions and circulating pancreatic epithelial cells with attributes of cancer stem cells [34]. Recently, several studies have also used lineage tracking to determine EMT status to assess the roles of EMT-inducing transcription factors in tumor progression and metastasis in transgenic mouse models. These studies suggested that the
contribution of EMT to cancer progression/metastasis and resistance to therapy depends on tumor type and tissue origin [39–41]. In the current study, we used MS-IHC to directly characterize individual tumor cells that co-express epithelial and mesenchymal markers during tumor progression, from cystic lesions to papillary adenomas and solid carcinomas, in the kidneys of Tsc2−/− mice. Based on our data, we propose a new model of EMT activation during tumor progression.

Most tumors in patients with TSC are benign (and often classified as hamartomas). Nonetheless, malignant and metastatic variants of TSC-associated RCC and malignant AML can develop, and a metastatic mechanism also appears to be involved in the pathogenesis in TSC2-associated pulmonary LAM [42]. Lung metastasis can occur from renal cancers in Tsc1−/− mice, while there is little evidence of metastatic disease from renal tumors in Tsc2−/− mice [5]. It may be interesting, therefore, to investigate the relationship of EMT to LAM [33] and to tumor progression and lung metastasis in Tsc1−/− mice.

We and others previously reported that rapamycin and ATP-competitive PI3K/mTOR dual inhibitors such as GSK2126458 and NVP-BEZ235 are effective for treating renal tumors in Tsc2−/− mice [29,43]. In the current study, we compared the therapeutic efficacy of AZD2014 (an ATP-competitive dual inhibitor of mTORC1/mTORC2) and rapamycin for renal tumors in these mice and found that both agents effectively reduced tumor burden. As expected, AZD2014 consistently inhibited both mTORC1 and mTORC2, while rapamycin strongly inhibited mTORC1 but exhibited only a partial inhibitory effect on mTORC2 [27–29]. Tumor cells insensitive to rapamycin were reported to be sensitive to AZD2014 in vitro [44,45]. AZD2014 also enhanced the radiosensitivity of glioblastoma stem-like cells in vitro and in vivo in a preclinical study [46]. In a xenograft mouse model of renal carcinoma, AZD2014 was reported to be a more effective treatment than rapamycin [28]. In contrast, we did not observe any superiority of AZD2014 over rapamycin in antitumor efficacy, possibly reflecting differences in tumor types and model systems. In a first-in-human pharmacokinetic and pharmacodynamic study, partial responses to AZD2014 were seen in a patient with pancreatic cancer and a patient with breast cancer [47]. However, a recent randomized phase 2 clinical trial suggested that AZD2014 was not as effective as everolimus (a rapamycin derivative) for VEGF-refractory metastatic clear cell renal cancer [48]. Combination of AZD2014 with other antitumor agents may improve therapeutic efficacy as described in preclinical models of various malignancies [49]. Over 20 clinical trials of cancer treatment have been initiated using combination therapy of AZD2014 with other antitumor agents in the last year (https://clinicaltrials.gov/ct2/results?cond=azd2014&term=&cntry1=&state1=&recrs=). To date, there are no reports of treatment of TSC patients using ATP-competitive PI3K/mTOR inhibitors, but a clinical trial has recently been planned to treat patients with TSC1/2 mutated refractory solid cancers using AZD2014 (https://www.findmecure.com/clinicaltrials/show/nci03166176). Considering the promising but partial response of TSC-associated tumors to rapamycin or its derivatives [20–23], further studies are warranted to compare the therapeutic efficacy of AZD2014 with rapamycin or its derivatives in clinical settings.

In conclusion, we have established that both AZD2014 and rapamycin suppress EMT and reduce the burden of all types of renal tumors in Tsc2−/− mice. We identified only a single large solid tumor that was resistant to AZD2014. Suppression of EMT may contribute to the antitumor efficacy of these agents for TSC-associated tumors. Liao et al. reported that both AZD2014 and rapamycin suppressed EMT in hepatoma cells, with AZD2014 having stronger effects [26]. Torin 1 (another ATP-competitive mTORC1/mTORC2 inhibitor) and rapamycin also suppressed EMT in glioblastoma cells [50]. EMT is activated and controlled through multiple complex regulatory networks in tumors [13,14]. Targeting these networks in combination with mTOR inhibition may provide opportunities for the therapy of refractory tumor types and eradication of cancer stem cells. Further studies are required for the full dissection of the signaling pathways involved in EMT in TSC-associated tumors, including further investigation of TGFβ signaling, a potent driver of EMT and tumor progression.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.neo.2019.05.003.

Conflict of Interest Statement
The authors declare no conflict of interest.

Acknowledgements
We would like to thank Dr. David Kwiatkowski for providing the Tsc2−/− mouse model. This project was supported by the Wales Gene Park, UK, and the Tuberous Sclerosis Association, UK.

References
[1] Consortium ECTS (1993). Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75(7), 1305–1315.
[2] Bjornsson J, Shorr MP, and Kwiatkowski D J (1996 Oct). Henske EP tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol 149(4), 1201–1208.
[3] Yang P, Cornejo KM, Sadow PM, Cheng L, Wang M, and Xiao Y, et al (2014). Renal cell carcinoma in tuberous sclerosis complex. Am J Surg Pathol 38(7), 895–909.
[4] Guo J, Tretiakova MS, Trosell ML, Ounskoy AO, Fadare O, Sangio AR, Shen SS, Lopez-Beltran A, Mehra R, and Heider A, et al (2014 Nov). Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients. Am J Surg Pathol 38(11), 1457–1467.
[5] Wilson C, Idziaczeky S, Parry L, Guy C, Griffiths DF, and Landa L, et al (2005). A mouse model of tuberous sclerosis 1 showing background specific early postnatal mortality and metastatic renal cell carcinoma. Hum Mol Genet 14(13), 1839–1850.
[6] Onda H, Lueck A, Marks PW, Warren HB, and Kwiatkowski DJ (1999). Tsc2−/− mice develop tumors in multiple sites that express geholin and are influenced by genetic background. J Clin Investig 104(6), 687–695.
[7] Yang J, Kalogerou M, Samuel PA, Zhang Y, Griffiths DF, and Gallacher J, et al (2015). Renal tumours in a Tsc2−/− mouse model do not show feedback inhibition of Ake and are effectively prevented by rapamycin. Oncogene 34(74), 922–931.
[8] Kalogerou M, Zhang Y, Yang J, Garahran N, Paisley S, and Tokarczuk P, et al (2012). T2 weighted MRI for assessing renal lesions in transgenic mouse models of tuberous sclerosis. Eur J Radiol 81(7), 2060–2064.
[9] Henske EP, Wessner LL, Golden J, Scheithauer BW, Vortmeyer AO, Zhuang Z, Klein-Szanto AJ, and Kwiatkowski DJ (1997 Dec). Yeung RS Loss of tuberin in both subependymal giant cell astrocytomas and angiomylolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. Am J Pathol 151(6), 1639–1647.
[10] Tyburyce MY, Jezowski S, Malinowska IA, Cherkulak Y, Pugh TJ, Wu CL, Nussbaum RL, Seppo S, Dzik T, and Kotulska K, et al (2015 Apr 1). A shower of second hit events as the cause of multifocal renal cell carcinoma in tuberous sclerosis complex. Hum Mol Genet 24(7), 1836–1842.
[11] Guettin DA and Sabatini DM (2007). Defining the role of mTOR in cancer. Cancer Cell 12(1), 9–22.
[12] Lamouille S, Xu J, and Derynck R (2014). Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15(3), 178–196.
[13] Kalluri R and Weinberg RA (2009). The basics of epithelial-mesenchymal transition. J Clin Invest 119(6), 1420–1428.
Thiery JP, Acloque H, Huang RY, and Nieto MA (2009). Epithelial-mesenchymal transitions in development and disease. *Cell* **139**(5), 871–890.

Nieto MA, Huang RY, Jackson RA, and Thiery JP (2016). EMT: 2016. *Cell* **166**(1), 21–45.

Lambert AW, Parthasarirman DR, and Weinberg RA (2017). Emerging biological principles of metastasis. *Cell* **168**(4), 670–691.

Piva F, Giuliani M, Santoni M, Occhipinti G, ScarPELLI M, and Lopez-Beltran A, et al (2016). Epithelial to mesenchymal transition in renal cell carcinoma: implications for cancer therapy. *Mol Diagn Ther* **20**(2), 111–117.

Barnes EA, Kenerson HL, Jiang X, and Yeung RS (2010 Oct). Tuberin regulates EMT. *Nat Rev Urol* **7**(10), 467–473.

Bi XG, Guo L, Wang XL, Wei Q, Du Q, Jiang WH, Zheng GY, Zhang HT, Ma XL, and Huang Q, et al (2013). Calcineurin inhibition induces epithelial-to-mesenchymal transition in renal cell carcinoma. *Oncotarget* **4**(20), 101–117.

Boy D, Gagnon F, Bissonnette R, Villeneuve M, Godbout J, and Lefebvre V, et al (2015). Epithelial-to-mesenchymal transition in renal cell carcinoma: implications for cancer therapy. *Mol Diagn Ther* **22**(3), 209–221.

Piva F, Giuliani M, Santoni M, Occhipinti G, Scarpelli M, and Lopez-Beltran A, et al (2016). Epithelial to mesenchymal transition in renal cell carcinoma: implications for cancer therapy. *Mol Diagn Ther* **20**(2), 111–117.

Karbownikczek M, Yu J, and Henske EP (2003). Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures. *Am J Pathol* **162**(2), 491–500.

Piva F, Giuliani M, Santoni M, Occhipinti G, ScarPELLI M, Lopez-Beltran A, Cheng L, Principato G, and Montironi R (2016). Epithelial to mesenchymal transition in renal cell carcinoma: implications for cancer therapy. *Mol Diagn Ther* **20**(2), 111–117.